Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury
NCT03229031 is registered in ClinicalTrials.gov with Eusol Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury
- Lead sponsor
- Eusol Biotech Co., Ltd.
- Phase
- Phase 3
- Overall status
- Suspended
- Start date
- March 7, 2018
- Completion date
- December 31, 2026
- Enrollment
- 160 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.